NCT06159166 2026-04-13
Mirda
Johns Hopkins University
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT07521657 2026-04-13
NF118
University of Alabama at Birmingham
Phase 2 Not yet recruiting
NCT03962543 2026-04-08
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT05028166 2026-03-27
Individual Patient Compassionate Use of Mirdametinib
SpringWorks Therapeutics, Inc.
Available
NCT04923126 2026-02-04
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT07237100 2025-11-19
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Sutter Health
Phase 2 Recruiting
NCT02096471 2019-01-10
MEK Inhibitor
University of Alabama at Birmingham
Phase 2 Completed